11/22
07:15 am
clsd
Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Landscape Research 2024 [Yahoo! Finance]
Medium
Report
Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Landscape Research 2024 [Yahoo! Finance]
11/16
03:06 am
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/15
06:04 pm
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Low
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
11/15
01:50 pm
clsd
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy [Yahoo! Finance]
Low
Report
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy [Yahoo! Finance]
11/15
06:59 am
clsd
Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/14
08:15 am
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
11/13
08:05 am
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Low
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
11/13
02:26 am
clsd
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ... [Yahoo! Finance]
Medium
Report
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ... [Yahoo! Finance]
11/12
04:12 pm
clsd
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
04:05 pm
clsd
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
11/11
07:33 am
clsd
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Report Preview: What to Look For [Yahoo! Finance]
Medium
Report
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Report Preview: What to Look For [Yahoo! Finance]
11/10
08:07 am
clsd
Even after rising 13% this past week, Clearside Biomedical (NASDAQ:CLSD) shareholders are still down 77% over the past three years [Yahoo! Finance]
Low
Report
Even after rising 13% this past week, Clearside Biomedical (NASDAQ:CLSD) shareholders are still down 77% over the past three years [Yahoo! Finance]
11/8
11:07 pm
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/8
04:06 am
clsd
Santen, Arctic Vision sign deal for ARVN001 to treat UME [Yahoo! Finance]
Medium
Report
Santen, Arctic Vision sign deal for ARVN001 to treat UME [Yahoo! Finance]
11/7
09:05 am
clsd
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
Low
Report
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
11/6
07:05 am
clsd
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
Medium
Report
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
11/4
07:20 am
clsd
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors [Yahoo! Finance]
Low
Report
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors [Yahoo! Finance]
11/4
07:05 am
clsd
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
Low
Report
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
10/31
07:11 am
clsd
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 [Yahoo! Finance]
Low
Report
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 [Yahoo! Finance]
10/31
07:05 am
clsd
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
Low
Report
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
10/22
07:05 am
clsd
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
High
Report
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
10/18
11:01 pm
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
High
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
10/14
12:46 pm
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Low
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
10/10
08:40 am
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its price target raised by analysts at Needham & Company LLC from $4.00 to $6.00. They now have a "buy" rating on the stock.
Low
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its price target raised by analysts at Needham & Company LLC from $4.00 to $6.00. They now have a "buy" rating on the stock.
10/9
10:31 am
clsd
Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study [Yahoo! Finance]
Medium
Report
Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study [Yahoo! Finance]